Open AccessDiffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden
Author(s) -
Kunal Patel,
Richard Everson,
Jingwen Yao,
Catalina Raymond,
J.W. Goldman,
Jacob Schlossman,
Joseph Tsung,
Caleb Tan,
Whitney Pope,
Matthew Ji,
Nhung Nguyen,
Albert Lai,
Phioanh Leia Nghiemphu,
Linda M. Liau,
Timothy F. Cloughesy,
Benjamin M. Ellingson
Publication year - 2020
Publication title -
neurosurgery/neurosurgery online
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.455
H-Index - 198
eISSN - 1081-1281
pISSN - 0148-396X
DOI - 10.1093/neuros/nyaa135
Subject(s) - bevacizumab , medicine , effective diffusion coefficient , magnetic resonance imaging , imaging biomarker , glioblastoma , cohort , biomarker , oncology , glioma , radiology , nuclear medicine , chemotherapy , cancer research , biochemistry , chemistry
Diffusion magnetic resonance (MR) characteristics are a predictive imaging biomarker for survival benefit in recurrent glioblastoma treated with anti-vascular endothelial growth factor (VEGF) therapy; however, its use in large volume recurrence has not been evaluated.